Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | RAB9A | P51151 | 7/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | LAP3 | P28838 | 2/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL7202878 | 0.81 | RAB9A (0.66) | NPC1RAB9ATSHREPHX2 | |
| SCHEMBL29429363 | 0.79 | NPC1 (0.62) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL9571959 | 0.79 | NPC1 (0.62) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL7764162 | 0.79 | CA12 (0.65) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL29505833 | 0.77 | NPC1 (0.56) | NPC1RAB9ATSHRCA12CA1 | |
| SCHEMBL1990363 | 0.76 | NPC1 (0.69) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL295136 | 0.76 | NPC1 (0.69) | NPC1RAB9AEPHX2 | |
| SCHEMBL5696271 | 0.76 | NPC1 (0.59) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL28155502 | 0.76 | HPGD (0.51) | TSHR | |
| SCHEMBL5120704 | 0.75 | RAB9A (1.00) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008814-A1 | Pseudomycin phosphate prodrugs | ELI LILLY AND COMPANY | 2003-01-09 | — | — | US | disclosed |
| US-20030008814-A1 | Pseudomycin phosphate prodrugs | ELI LILLY AND COMPANY | 2003-01-09 | — | — | US | disclosed |
| WO-2001041534-A3 | PSEUDOMYCIN PHOSPHATE PRODRUGS | LILLY CO ELI (US) | 2001-11-22 | — | — | WO | disclosed |
| WO-2001041534-A2 | PSEUDOMYCIN PHOSPHATE PRODRUGS | ELI LILLY AND COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |
| WO-2001041534-A2 | PSEUDOMYCIN PHOSPHATE PRODRUGS | ELI LILLY AND COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008814-A1 | Pseudomycin phosphate prodrugs | PMM2, ME1, BPGM | NPC1 1736/4885RAB9A 1985/4885TSHR 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.